Definitive Contract 75N91023C00010

This $354,908 firm fixed price definitive contract was awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Ubiquitx Inc., a New York-based for-profit small business. The contract is for the development of the Ubiquibody Platform for Targeted Degradation of Oncogenic Fusion Proteins, as initially solicited under the Institute's Small Business Innovation Research Innovative Concept Award Program. This total small business set-aside award will support Ubiquitx's efforts to demonstrate technical feasibility and proof-of-concept for its therapeutic technology, which aims to facilitate the targeted degradation of pediatric and rare cancer-causing fusion proteins. Work will be performed in New York through February 2025.